• New Cara mobile app improves health decisions
  • Cara’s AI takes into account each individual’s health profile and their symptoms to provide a more accurate and personalized recommendation about what they might have
  • Cara’s AI technology will provide intelligent follow-up to the consumer to ensure they are getting the healthcare support and management they need
  • The Cara mobile app is powered by a next-generation AI software engine that was developed by a global team of doctors over the last 5 years
  • Treatment.com is a healthcare technology company that is harnessing the power of AI to help Canadians improve their health
  •  Treatment.com International Inc. (TRUE) is up 0.17 per cent and is trading at C$5.85 at 12:06 pm ET

 Treatment.com International Inc. (TRUE) has developed an AI platform to empower better health decisions.

Treatment is launching their first product, Cara.Health that will leverage the proprietary AI to provide health insights and health management in a supportive digital tool.

1 billion consumers turn to Google everyday to look up a health question.

The results are not personalized or considerate of their health history, and can lead to confusion and fear.

Cara’s AI takes into account each individual’s health profile and their symptoms to provide a more accurate and personalized recommendation about what they might have.

“With Cara, the consumer can simply type in a symptom that’s bothering them, and get a very accurate and unique assessment for the condition they might have, as well as information about treatment and prevention,” says John Fraser, CEO of Treatment.com, the founders of Cara.Health.

“We know this will help millions of people, especially those who have regular health concerns or who are looking after their family and having to make healthcare decisions every day,” added Fraser.

Cara’s AI technology will provide intelligent follow-up to the consumer to ensure they are getting the healthcare support and management they need.

The AI engine builds a unique health profile around each individual by pulling in a multitude of data inputs, including wearable smart technology and other digital healthcare monitoring and tracking apps.

The Cara mobile app is powered by a next-generation AI software engine that was developed by a global team of doctors over the last 5 years.

Paired with the ability to track, monitor and follow up with every user, and their family members, the Cara app is designed to truly help put healthcare power in the patient’s hands.

The Cara app is launching for free this summer in Canada and the US.

CEO John Fraser comments,

“With better information, consumers can make better decisions, and their overall health will be better managed.”

Treatment.com is a healthcare technology company that is harnessing the power of AI to help Canadians improve their health through personalized recommendations and insights.

Based in Vancouver, the company spent the last five years working with a team of world-class doctors, engineers, mathematicians, and AI specialists to develop a complex AI engine that leverages the most robust, personalized data to generate highly predictive and accurate insights.

 Treatment.com International Inc. (TRUE) is up 0.17 per cent and is trading at C$5.85 at 12:06 pm ET.

More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.